Profile
Harlow John B. Jr. is a corporate executive who, as of the most recent SEC filing dated July 13, 2026, served as Chief Commercial Officer of Esperion Therapeutics, Inc. In this role he is responsible for Esperion's commercial strategy, including product planning, sales, marketing, and payer and market-access activities for the company's lipid-lowering therapies. The available SEC filing context confirms his role at Esperion but does not provide a detailed public history of his career.
| Role | Chief Commercial Officer |
|---|
| Notability | 25/100 |
|---|
Board memberships
- Esperion Therapeutics, Inc.
Awards & honors
- Listed as Chief Commercial Officer of Esperion Therapeutics in SEC filings (as of 2026).
Frequently Asked Questions
Who is Harlow John B. Jr.?
Harlow John B. Jr. is a corporate executive who, as of the most recent SEC filing dated July 13, 2026, served as Chief Commercial Officer of Esperion Therapeutics, Inc. In this role he is responsible for Esperion's commercial strategy, including product planning, sales, marketing, and payer and market-access activities for the company's lipid-lowering therapies. The available S…
How many SEC Form 4 filings has Harlow John B. Jr. submitted recently?
1 primary Form 4 filings in the last 90 days, covering 1 company.
Where can I see all of Harlow John B. Jr.'s SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.